What the Novavax results mean for the UK’s vaccine rollout
Expected approval of the new jab would leave UK with tens of millions of excess doses

Britain’s Covid vaccines rollout is on course to get a fresh boost after a new jab was found to be 89.3% effective in large-scale UK trials.
The UK has already secured 60 million doses of the Novavax vaccine, which will now be assessed by the Medicines and Healthcare products Regulatory Agency and could be “delivered in the second half of this year” if approved, the BBC reports.
Stan Erck, chief executive of Novavax, said the results from the UK phase three trial were “spectacular” and “as good as we could have hoped”.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
How does it work?
The Novavax vaccine “works in a slightly different way to the ones that are already available”, writes BBC health editor Michelle Roberts, “but does the same job of teaching the body's immune system to recognise and fight the pandemic virus”.
To develop the jab, researchers placed “a modified gene into a virus, called a baculovirus, and allowed it to infect insect cells”, ITV reports. Spike proteins from these cells were then “assembled into nanoparticles”, which “while they look like coronavirus, cannot replicate or cause Covid-19”, the broadcaster continues.
These nanoparticles “are then injected into the body via the vaccine where the immune system mounts an antibody response” that helps to protect the patient against future Covid-19 infection.
As the BBC's Williams adds, the Novavax jab also “appears to be effective against emerging and more infectious variants of coronavirus”, including the South African version - a result that scientists had feared “might not be possible because the vaccines were all designed to match the original virus”.
What does it mean for the UK?
If approved, Novavax will be the fourth coronavirus vaccination to get the green light for use in the UK.
And having ordered tens of millions of doses of the jab, along with stocks of “more new vaccines coming down the tracks”, Britain could be left in the “promising position” of possessing “more doses than it needs to vaccinate the entire population”, says Politico's London Playbook.
The promising trial results for Novavax - which would be manufactured in Stockton-on-Tees - have been welcomed by the government.
Health Secretary Matt Hancock said that the “NHS stands ready to roll this vaccine out as quickly as possible to those most at risk if it is authorised”.
Meanwhile, Boris Johnson welcomed the “good news” in a tweet in which the prime minister also thanked “all the volunteers who made these results possible”.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Chas Newkey-Burden has been part of The Week Digital team for more than a decade and a journalist for 25 years, starting out on the irreverent football weekly 90 Minutes, before moving to lifestyle magazines Loaded and Attitude. He was a columnist for The Big Issue and landed a world exclusive with David Beckham that became the weekly magazine’s bestselling issue. He now writes regularly for The Guardian, The Telegraph, The Independent, Metro, FourFourTwo and the i new site. He is also the author of a number of non-fiction books.
-
What does the Le Pen verdict mean for the future of French politics?
TODAY'S BIG QUESTION Convicted of embezzlement and slapped with a five year ban on running for public office, where does arch-conservative Marine Le Pen go from here — and will the movement she leads follow?
By Rafi Schwartz, The Week US Published
-
Discount stores were thriving. How did they stumble?
The Explainer Blame Walmart — and inflation
By Joel Mathis, The Week US Published
-
Kaja Kallas: the EU's new chief diplomat shaping the future of European defense
In the Spotlight Former Estonian Prime Minister's status as an uncompromising Russia hawk has gone from liability to strength
By David Faris Published
-
Five years on: How Covid changed everything
Feature We seem to have collectively forgotten Covid’s horrors, but they have completely reshaped politics
By The Week US Published
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
By Peter Weber, The Week US Published
-
Why is the FDA slow to ban food additives?
Today's big question A legal loophole lets things slide
By Devika Rao, The Week US Published
-
How close are we to a norovirus vaccine?
Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
By David Faris Published
-
HMPV is spreading in China but there's no need to worry
The Explainer Respiratory illness is common in winter
By Devika Rao, The Week US Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
Will the murder of a health insurance CEO cause an industry reckoning?
Today's Big Question UnitedHealthcare CEO Brian Thompson was shot and killed in what police believe was a targeted attack
By Justin Klawans, The Week US Published
-
What are Trump's plans for public health?
Today's Big Question From abortion access to vaccine mandates
By Devika Rao, The Week US Published